Bronchogen Research Overview (also known as Bronchogen peptide, Ala-Glu-Asp-Ala tetrapeptide, Khavinson bronchial bioregulator)
A peptide studied for its influence on airway structure and pulmonary inflammation regulation. Research has focused on applications involving chronic bronchitis models, post-infection respiratory recovery, and long-term lung-tissue stress.
What Is Bronchogen?
Bronchogen is a tetrapeptide bioregulator developed by Professor Vladimir Khavinson's team targeting bronchopulmonary tissue — specifically the bronchi and bronchioles. It is one of the organ-specific cytomedins in the Khavinson system, designed to restore normal functional gene expression in aging or damaged bronchial epithelial cells.
Target Tissue and Aging
The bronchial epithelium serves as the primary interface between the respiratory system and the external environment. With aging, bronchial epithelial cell function declines: mucociliary clearance slows, surfactant production decreases, and local immune defense weakens. Bronchogen is designed to restore normal bronchial cell activity by acting on chromatin structure and normalizing the epigenetic regulation of key functional genes.
Research Applications
Animal studies have shown Bronchogen to reduce morphological signs of bronchial aging, improve mucociliary clearance parameters, and enhance local bronchial immune defense. Russian clinical research has documented improvements in respiratory function parameters and reduction in recurrent respiratory infections in elderly subjects receiving Bronchogen as part of comprehensive bioregulator protocols.
Quick Reference
| Literature-Reported Dose Range | 1–2 mg per injection |
| Literature-Reported Frequency | Once daily |
| Sites Reported in Studies | SubQ: abdomen, thigh, or upper arm |
| Timing | AM or PM, consistent daily timing |
| Literature-Reported Cycle Length | 20–30 days per course |
| Literature-Reported Washout | 2–3 courses per year; minimum 2 months off, 2–3× per year |
| Storage | Lyophilized: 2–8°C; Reconstituted: use within 30 days at 2–8°C; protect from light |
Research Indications
Bronchopulmonary Aging and Mucociliary Clearance
Bronchogen was specifically developed to restore normal functional gene expression in aging bronchial epithelial cells. Aging bronchial epithelium shows reduced mucociliary transport velocity, impaired surfactant production, and weakened barrier function. Animal studies demonstrate that Bronchogen administration normalizes these parameters and reduces morphological signs of bronchial aging.
Chronic Obstructive Airway Disease
Russian clinical research documents improvements in respiratory function parameters and reduction in recurrent respiratory infections in elderly subjects receiving Bronchogen as part of comprehensive bioregulator protocols. The mechanism — epigenetic normalization of bronchial cell gene expression — is consistent with the broader Khavinson bioregulator model.
Post-Infection Pulmonary Recovery
Khavinson groups have explored bronchial peptides in post-infection recovery contexts, including bacterial pneumonia and viral respiratory illness. The rationale is that bronchial epithelial damage from infection accelerates epigenetic dysregulation; Bronchogen's chromatin-level effects may support restoration of normal epithelial gene expression after injury.
Pulmonary Immune Defense and Mucosal Immunity
Local bronchial immune function — secretory IgA production, alveolar macrophage activity, bronchial mast cell regulation — declines with age. Bronchogen's tissue-specific action on bronchial epithelial cells may indirectly support the local immune niche by restoring the epithelial substrate that hosts these immune populations.
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
| Research Application | Dose | Frequency | Route |
|---|
| Loading Phase | 500 mcg (0.5 mg) | Once daily | SubQ |
| Standard Protocol | 1 mg | Once daily | SubQ |
| Maintenance | 1–2 mg | Once daily during course | SubQ |
Peptide Interactions
Endoluten targets the pineal gland, whose melatonin output regulates immune timing and circadian immune function. Combining Endoluten with Bronchogen addresses both the pulmonary epithelium (Bronchogen) and the systemic neuroendocrine immune regulator (Endoluten) — a combination used in Khavinson geroprotective longevity protocols.
Thymic peptides (Thymalin and Thymogen) restore T-cell populations and systemic cellular immunity. Combined with Bronchogen's local bronchial epithelial support, this addresses both systemic immune competence and the specific local immune niche of the airways.
The Khavinson bioregulator system is designed for multi-organ use. Bronchogen can be co-administered with other organ-targeting peptides (Vesugen, Livagen, Pielotax, etc.) as part of comprehensive geroprotective protocols. No pharmacokinetic interactions have been reported between Khavinson peptides.
While there is no direct pharmacokinetic conflict between Bronchogen and bronchodilators, the timing of administration should be separated to avoid confounding assessment of respiratory effects. Administer Bronchogen separately from bronchodilator doses when monitoring respiratory function.
Reported Research Timeline
Week 1 (reported in cited studies): Little visible change; early tissue signaling begins.
Weeks 2–3 (reported in cited studies): Possible improvement in cough, mucus handling, or airway comfort in responsive models.
Week 4 (reported in cited studies): Better respiratory resilience and reduced irritation may become more noticeable.
Beyond the cycle: Some writeups describe effects lasting for months after the cycle ends, consistent with the bioregulator model of longer tissue normalization.
Safety Notes
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
Mild injection-site irritation is the most commonly reported adverse effect
Not recommended during pregnancy or breastfeeding
Product quality and sterility are critical — source from vendors providing a valid Certificate of Analysis
Long-term safety data in humans is limited; extrapolations from animal studies should be interpreted cautiously
Seek Medical Attention If:
Persistent injection site reactions (redness, pain, or swelling beyond 48 hours)
Signs of allergic reaction (hives, difficulty breathing, or facial swelling)
Severe or unusual symptoms following administration
Always consult a licensed physician before and during use
Quality Indicators
Verified Marker
Recognized Khavinson-Protocol Supplier
Bronchogen was developed at the St. Petersburg Institute of Bioregulation and Gerontology. Authentic pharmaceutical-grade Bronchogen is available as a lyophilized injectable from recognized Russian/Eastern European manufacturers. Products claiming "Bronchogen" without a clear tetrapeptide sequence (Ala-Glu-Asp-Ala) and lyophilized injection-grade preparation are suspect.
Verified Marker
Injectable-Grade Lyophilized Powder
As a research-grade injectable bioregulator, Bronchogen should be a white lyophilized powder reconstituted with bacteriostatic water or sterile saline. Clear, colorless solution post-reconstitution. No sediment or discoloration.
Quality Concern
Non-Pharmaceutical "Spray" or "Drop" Oral Claims
While oral supplement-grade Bronchogen capsules or sublingual drops exist (Cytogen product line), these have dramatically different bioavailability compared to the injectable form used in Khavinson research. Claims of bioequivalence between oral supplement and injectable Bronchogen are unsupported.
Quality Concern
Room-Temperature Shipping Without Cold Pack
Like all injectable peptide bioregulators, Bronchogen requires cold-chain shipping and refrigerated storage. Products shipped without temperature control raise integrity concerns about the peptide's folding and activity at time of use.
Research Citations
- Short Exogenous Peptides Regulate Expression of CLE, KNOX1, and GRF Family Genes in Nicotiana tabacum
Fedoreyeva LI, Dilovarova TA, Ashapkin VV, 2017, Biochemistry (Mosc) - Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA
Fedoreyeva LI, Kireev II, Khavinson VKh, 2011, Biochemistry (Mosc) - Modulating Effect of Peptide Therapy on the Morphofunctional State of Bronchial Epithelium in Rats with Obstructive Lung Pathology
Kuzubova NA, Lebedeva ES, Dvorakovskaya IV, 2015, Bull Exp Biol Med
Research Focus
Lung health, Bronchial tissue restoration, Anti-aging, Respiratory function, Bronchopulmonary protection
Verified Vendors Carrying Bronchogen
Frequently Asked Questions
What should researchers watch for with Bronchogen?
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
What should researchers expect over time with Bronchogen?
Week 1 (reported in cited studies): Little visible change; early tissue signaling begins.
How is Bronchogen typically administered in research?
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
Browse all peptides in the Encyclopedia →